Biocon to start selling breast cancer drug in India in February
MUMBAI (Reuters) - Biocon Ltd(BION.NS) said its generic version of Roche's(ROG.VX) Herceptin breast cancer treatment would be available to patients in India from the first week of February.
Bangalore-based Biocon jointly developed biosimilar trastuzumab, which received the Indian drug regulator's marketing approval in November, with U.S.-based Mylan Inc.
About 150,000 people are diagnosed with breast cancer every year in India, of which 25 percent are eligible for treatment with trastuzumab, Biocon said.
Roche decided not to pursue a patent application for its breast cancer drug Herceptin in India, paving the way for generic drugmakers to produce cheaper copies, known as biosimilars because they are not identical to the original drug.
Global sales for Herceptin were valued at about $6.4 billion in 2012, including about $21 million in India, Biocon said.
(Reporting by Aradhana Aravindan; Editing by Sonya Hepinstall)
- Tweet this
- Share this
- Digg this
- Apple sells more than 10 million new iPhones in first 3 days
- UPDATE 3-Apple sells more than 10 mln new iPhones in first 3 days
- India's Mars mission a step closer to success with engine test
- Israel's Mossad takes hunt for foreign spies and informants online
- Modi to observe strict fast during maiden trip to U.S.
The finance ministry is increasingly optimistic that it can meet a tough fiscal deficit target, helped by a 12 percent decline in global crude oil prices since Prime Minister Narendra Modi took charge in May. Full Article